Back to search
FDAFDA · Food and drugs·Recall number D-0893-2022

Losartan Pot/HCTZ 100/12.5 mg 90 Tabs NDC 72189-290-90 Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg. For Macleods Pharma USA, Inc. Plainsboro, NJ 08540

Published June 1, 2022 · Recall initiated: May 11, 2022

Summary

FDA records drug Class II recall D-0893-2022, published June 1, 2022 and initiated May 11, 2022. Recalling firm: Direct Rx; Status: Terminated; Reported quantity: 11 bottles; Lot: Lot: 25OC2116 Exp. 5/31/23. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits .

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
Manufacturer
Direct Rx
Distributor
FL
Lot
Lot: 25OC2116 Exp. 5/31/23
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Losartan Pot/HCTZ 100/12.5 mg 90 Tabs NDC 72189-290-90 Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg. For Macleods Pharma USA, Inc. Plainsboro, NJ 08540 recalled?

Yes. FDA published recall D-0893-2022 on June 1, 2022. Reported hazard: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits .

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE.